SERNIVO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SERNIVO (SERNIVO).
SERNIVO (clobetasol propionate) is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
| Metabolism | Clobetasol propionate is metabolized primarily in the liver via ester hydrolysis and subsequent conjugation. The primary metabolic pathway involves hydrolysis of the propionate ester to form clobetasol, followed by glucuronidation and sulfation. |
| Excretion | Primarily renal excretion of inactive metabolites; <5% unchanged. Minor biliary/fecal elimination. |
| Half-life | Approximately 3 hours (parent drug); clinical duration extended via formulation. |
| Protein binding | Approximately 70-80% bound to corticosteroid-binding globulin and albumin. |
| Volume of Distribution | Not reported for topical formulation; systemic absorption minimal. |
| Bioavailability | Topical: negligible systemic bioavailability (<1%) with intact skin. |
| Onset of Action | Topical: within 2 weeks of daily application for plaque psoriasis. |
| Duration of Action | Once-daily application for psoriasis; therapeutic effect maintained with continued use. |
Apply a thin layer to affected area twice daily for up to 2 weeks.
| Dosage form | SPRAY |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dosage adjustment recommended; use with caution due to potential age-related skin atrophy. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SERNIVO (SERNIVO).
| Breastfeeding | It is unknown if topically applied clobetasol propionate is excreted in human milk. Systemic absorption is minimal, but with large areas or occlusive use, significant absorption may occur. Caution should be exercised. M/P ratio is not available. |
| Teratogenic Risk | SERNIVO (clobetasol propionate) is a topical corticosteroid. Systemic absorption is low with topical use, but prolonged or extensive application may increase risk. Animal studies show corticosteroids can cause teratogenicity (cleft palate, growth restriction). Human data on topical use in pregnancy are insufficient. Use only if potential benefit justifies risk. First trimester: consider risk of cleft palate; second/third trimester: risk of fetal growth restriction and adrenal suppression. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to clobetasol propionate or any component of the formulation","Untreated bacterial, fungal, viral, or parasitic skin infections"]
| Precautions | ["Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria.","Pediatric patients may be more susceptible to systemic toxicity due to larger skin surface-to-body weight ratio.","Prolonged use may result in atrophy of the skin, striae, and telangiectasias.","Use on face, intertriginous areas, or under occlusion may increase systemic absorption.","Do not use in patients with known hypersensitivity to clobetasol propionate or any component of the formulation."] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of maternal adrenal suppression (fatigue, hypotension) if large areas are treated or occlusive dressings used. Fetal monitoring includes ultrasound for growth restriction if prolonged use. Newborns should be monitored for signs of adrenal suppression if maternal use was extensive near term. |
| Fertility Effects | No specific studies on fertility effects in humans. Animal studies with corticosteroids have shown impairment of fertility. The effect of topical clobetasol on human fertility is unknown. |